|
|
Article: Tysabri's Phase III Positive; Details Back Top-Line Data.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Further bolstering the companies' hopes that the withdrawn multiple sclerosis drug Tysabri might one day become available again, Biogen Idec Inc. and Elan Corp. plc disclosed full two-year data from their Phase III monotherapy trial with the compound.
Biogen Idec's stock (NASDAQ:BIIB) closed Wednesday at $36.45, down 25 cents. Dublin, Ireland-based Elan's (NYSE:ELN) shares fared better, ending the day at $4.29, up 52 cents, or 13.8 percent.
Specifically, two-year data from the AFFIRM Phase III monotherapy study presented Wednesday at the American Academy of Neurology meeting in Miami Beach, Fla., showed Tysabri (natalizumab) ...